FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Viz.ai Algorithm Cleared for Abdominal Aneurysms

FDA clears a Viz.ai 510(k) for its Viz AAA, an artificial intelligence algorithm intended to detect suspected abdominal aortic aneurysms.

latest-news-card-1
Human Drugs

Accelerated Approval Mulled for Biogens Tofersen

FDA reviewers appear open to considering accelerated approval for Biogens amyotrophic lateral sclerosis drug tofersen in patients with the superoxide ...

latest-news-card-1
Medical Devices

CDRH Modifies Electronic 510(k) Portal

CDRH adds more functionality to its medical device electronic submission portal to prepare for an all-electronic submission process.

latest-news-card-1
Human Drugs

FDA Input on Rare Disease Development Needed: PhRMA

Pharmaceutical Research and Manufacturers of America urges FDA to provide more input on the types of evidence that may be considered in rare disease d...

latest-news-card-1
Medical Devices

Keep Device Real-World Evidence Under NESTcc: MDMA

Medical Device Manufacturers Association says it would be wasteful and duplicative to use medical device user fee funds to advance real-world data/evi...

latest-news-card-1
Human Drugs

Athenex Cell Therapy on Clinical Hold

FDA issues a clinical hold against Athenex and Baylor College of Medicines kUR-501 after the death of a young heavily pretreated male patient.

latest-news-card-1
Medical Devices

Remote Assessments May Be Model for Device Inspections

Former CDRH Office of Compliance director Steven Silverman recommends device manufacturers look at FDAs remote regulatory assessment program as a temp...

latest-news-card-1
Biologics

Sarepta BLA Needs Panel Review: FDA

FDA tells Sarepta Therapeutics that it has decided to hold an advisory committee meeting to review its gene therapy BLA for SRP-9001 (delandistrogene ...

latest-news-card-1
Medical Devices

FDA Hits Olympus with Warning Letter

FDA issues Olympus Medical Systems a Warning Letter after inspecting the firms Tokyo facility and documenting GMP deficiencies.

latest-news-card-1
Biologics

Court OKs $25 Million Remicade Settlement

A federal judge approves a $25 million class action settlement involving Johnson & Johnsons Remicade (infliximab).